EARly Prevention of aTHeroma Progression

Inclusion Criteria: * Men or women at least 35 years of age * Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing \<50%) and CAC score \<300 in at least one segment of proximal or mid-portion of major epicardial coronary arteries * LDL cholesterol \<130mg/dl Exclusion Criteria: * History of stable angina, or acute coronary syndrome * History of transient ischemic attack, or stroke * Chronic kidney disease (eGFR\< 60ml/min) * Diabetes mellitus with microvascular complications or insulin therapy * Hypertriglyceridemia (triglyceride \>500mg/dl) * Any statin therapy in the past 4 weeks * Planned cardiac surgery or planned major non-cardiac surgery within 6 months. * Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible). * A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer. * Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study. * Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal). * History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s). * Unwillingness or inability to comply with the procedures described in this protocol. * Positive pregnancy test (all female subjects of childbearing potential must have a urine ß-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/ or within 7 days prior to randomization) or is known to be pregnant or lactating. * Hypersensitivity to Crestor * Skeletal muscle disease * Combination use with cyclosporine * Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption * Combination use of protease inhibitor